Sarepta Therapeutics (SRPT) Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 84.83% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (down 84.83% YoY), while the FY2025 annual figure was $58.6 million, down 84.31% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.4 million, down from $58.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $383.7 million in Q2 2022, with the low at $3.2 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $50.0 million (2024), against an average of $114.6 million.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 10759.65% in 2023, then slumped 93.9% in 2025.
• Sarepta Therapeutics' Accumulated Expenses stood at $5.0 million in 2022, then surged by 1488.62% to $78.7 million in 2023, then soared by 374.41% to $373.5 million in 2024, then slumped by 84.31% to $58.6 million in 2025, then plunged by 90.86% to $5.4 million in 2026.
• Business Quant data shows SRPT's Accumulated Expenses at $5.4 million in Q1 2026, $58.6 million in Q4 2025, and $3.5 million in Q3 2025.